- Conditions
- Breast Cancer
- Interventions
- capecitabine, adjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 394
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Fibroadenoma
- Interventions
- ECHOPULSE
- Device
- Lead sponsor
- Theraclion
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 4
- States / cities
- New York, New York • Charlottesville, Virginia
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 2,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 84 more
- Conditions
- Breast Cancer
- Interventions
- Breast MRI, Mammogram
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Gemcitabine and Capecitabine and Avastin
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 3
- States / cities
- Albuquerque, New Mexico • Providence, Rhode Island
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
- Interventions
- Samples
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Malignancies
- Interventions
- INCAGN01949, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Cyclophosphamide, Fludarabine, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, PD1 Inhibitor
- Drug · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Tetrathiomolybdate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Interventions
- counseling intervention, behavioral dietary intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis
- Other · Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 35 Years to 65 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- Evaluation of Cancer Risk Factors, Medical Chart Review, Study of Socioeconomic and Demographic Variables
- Procedure · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 30 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
- Interventions
- Fluciclatide Injection
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Breast Neoplasms, Bone and Bones
- Interventions
- Calcitriol, Exercise, Multivitamin
- Drug · Behavioral · Dietary Supplement
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- fenretinide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
- Drug · Biological · Procedure
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- High Risk for Breast Cancer
- Interventions
- Decision aid video, Genetic counseling informational brochure
- Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- Stereo Navigator Accessory to PEM Flex PET Scanner
- Device
- Lead sponsor
- Naviscan PET Systems
- Industry
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • Timonium, Maryland • Portland, Oregon + 2 more
- Conditions
- Breast Neoplasms
- Interventions
- High-Dose Chemo with Autologous BMT
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2002
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- 2-Fluorodeoxyglucose
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Capivasertib, Laboratory Biomarker Analysis, Olaparib, Pharmacological Study, Vistusertib
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 737 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Carboplatin, Paclitaxel, Pembrolizumab
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina